This small single-arm study gave 250 mg/day NMN to 11 healthy volunteers for 12 weeks and measured plasma NMN and NAD+ monthly.
Plasma NMN and NAD+ increased during supplementation, and postprandial insulin also increased. The size of the NMN and insulin changes varied widely between individuals.
No adverse symptoms were reported, but because there was no placebo group, the study cannot establish comparative clinical benefit or determine whether other changes were caused by NMN.
Key findings
Plasma NMN increased during oral supplementation.
Plasma NAD+ increased during supplementation.
Postprandial serum insulin increased, with substantial person-to-person variability.
No adverse symptoms were observed in the 11 participants.
The study had no control group.
What it cannot establish
Only 11 participants.
No placebo or untreated control group.
The main endpoints were biochemical rather than clinical outcomes.
Wide interindividual variability in NMN and insulin responses.
The study does not establish long-term benefit or safety.
HealthspanX claim boundary: This uncontrolled study supports plasma pharmacodynamic observations only. It does not establish anti-aging, metabolic, longevity, or disease-treatment benefits.
